Labcorp Holdings stock
Price history
+40.41% over the period1 year: from $261.47 (November 20, 2025) to $367.13 (November 20, 2026), +40.41%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $367.13 |
| October 30, 2026 | $361.39 |
| September 30, 2026 | $308.11 |
| August 31, 2026 | $332.66 |
| July 31, 2026 | $309.20 |
| June 30, 2026 | $280.00 |
| May 29, 2026 | $260.06 |
| April 30, 2026 | $256.80 |
| March 31, 2026 | $266.81 |
| February 27, 2026 | $289.12 |
| January 30, 2026 | $271.52 |
| December 31, 2025 | $250.88 |
| November 28, 2025 | $268.78 |
| November 20, 2025 | $261.47 |
At a glance
The company
Provides clinical laboratory testing, biopharma lab services, and digital pathology and patient platforms
Latest results
Quarter to September 30, 2026 · EPS $4.78 (estimate $4.65)
Dividend
TickerLandia's take on Labcorp Holdings
- Pricier than usual relative to earnings: P/E on the latest fiscal year 35 vs a median of 15 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 30 vs 34 (−10%) in a group of 9.
- Strong point: Market momentum (93/100 in its group). Weak point: Dividend (31/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.12% from the 52-week high
Analysts · 17 analysts
Average target$391.00+6.50% vs. price
Buy 13 · Hold 4 · Sell 0 · Buy
TickerLandia Fingerprint: Labcorp Holdings
Compared with similar companies: very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 888 North American stocks.
Pricelow38
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 30.2 44 Forward P/E 18.7 38 EV/EBITDA 15.5 42 Price/book 3.37 40 Price/sales 2.04 24 Profitabilitylow32
How much it earns on revenue and capital.
Metric Value Position in group ROE 11.4% 48 Gross margin 29.0% 13 Net margin 6.9% 31 ROA 5.5% 46 Operating margin 11.2% 20 Earnings stabilityaverage43
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 6.7% 24 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthlow39
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +3.20% 14 Average revenue growth (3 years) +5.55% 69 Revenue growth (year over year) +6.90% 35 Financial strengthlow38
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.73 38 Current ratio 1.41 31 Debt/equitycounts in reverse: lower means more financial strength 0.77 31 Interest coverage 6.72 52 Dividendlow31
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 0.8% 43 Payout ratio 23.7% 22 Consecutive dividend years 5 years 26 Market momentumvery strong93
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +21.98% 90 Relative strength (6 months) +53.40% 96 Distance from 200-day average +24.53% 98 1-year return +40.41% 88 Risklow23
How much the price swings.
Metric Value Position in group Volatility (60 days) 28.1% 30 Beta (1 year) 0.33 32 Maximum drawdown (12 months) 13.6% 6
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Labcorp Holdings is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Labcorp Holdings's P/E today is 35.1, above the median of its last 10 fiscal years (15.3; between 11.0 and 47.6 from 2016 to 2025). Labcorp Holdings's P/E (trailing 12 months): 30.1, −10% against the median of a group of 9 similar companies (33.6).
Compared with 9 similar companies
| Metric | Labcorp Holdings | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 30.1 | Low | |
| Forward P/E | 18.7 | Low | |
| Operating margin | 11.2% | Low | |
| ROE | 11.4% | Low | |
| Debt/equity | 0.77 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Labcorp Holdings. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$3.81B
Latest quarter · Q3 2026
Net income
$262.8M
Latest quarter · Q3 2026
Quarterly net margin
6.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $29.81B
- P/E
- 30.1
- EPS
- $12.20
- Volume
- 890.42K
- Daily trading
- €260.08M
- Dividend yield
- 0.78%
How Labcorp Holdings is changing
All resultsRevenue fell 0.0% a year on average over the last 5 years
Operating margin fell from 12.1% to 9.9%
Profits turn into cash: free cash flow equal to 156% of net income
Returns
Labcorp Holdings returns with dividends
$1,000 invested in Labcorp Holdings 5 years ago, on November 22, 2021, would be worth $1,593 today with dividends reinvested: +59.26% in total, +9.77% per year. On price alone it would be $1,506 (+50.60%).
| Period | Labcorp Holdings | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +13.62% | −10.40% | $1,136 |
| 6 months | +42.62% | −7.03% | $1,426 |
| Year to date | +46.34% | +0.95% | $1,463 |
| 1 year | +41.83% | +5.68% | $1,418 |
| 3 years | +79.49% | +51.96% | $1,795 |
| 5 years | +59.26% | +47.57% | $1,593 |
| 10 years | +258.32% | +214.37% | $3,583 |
Over the last 6 months it has done better than 89% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Labcorp Holdings: technical analysis
Labcorp Holdings is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 1.4% below its all-time closing high ($372.46, November 16, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- +24.53%
Support and resistance
Price areas where Labcorp Holdings has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$373.05+1.61%2 touches, last on November 12, 2026
- Last price$367.13
- Support$303.76−17.26%3 touches, last on October 2, 2026
- Support$291.35−20.64%3 touches, last on July 7, 2026
- Support$275.28−25.02%4 touches, last on June 10, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.33
- Volatility (60 sessions, annualised)
- 28.1%
- Largest fall in the last year
- −13.62%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Labcorp Holdings: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Labcorp Holdings has been April: +3.52% on average, positive in 22 years out of 37. The weakest has been August: −1.67% on average, positive in 19 years out of 37. November, the current month, has been positive in 22 years out of 36 (+0.58% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.21% | +2.98% | 22 of 36 |
| February | +2.50% | +0.21% | 21 of 36 |
| March | +0.28% | +1.03% | 22 of 36 |
| April | +3.52% | +2.63% | 22 of 37 |
| May | +1.30% | +1.68% | 20 of 37 |
| June | +2.33% | +2.77% | 22 of 37 |
| July | +1.00% | −0.61% | 18 of 37 |
| August | −1.67% | +0.02% | 19 of 37 |
| September | −1.01% | −3.12% | 15 of 37 |
| October | +0.83% | +1.98% | 21 of 37 |
| November | +0.58% | +1.21% | 22 of 36 |
| December | +1.12% | +2.35% | 25 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Labcorp Holdings and its competitors
With roughly 71,000 employees, Labcorp Holdings provides laboratory services organized in two segments, Diagnostics Laboratories and Biopharma Laboratory Services. Its menu of tests runs from routine blood chemistry, urinalysis, thyroid and HbA1c testing to specialty gene-based and esoteric tests covering areas such as oncology, cardiovascular disease, infectious disease, women's health, diagnostic genetics and pharmacogenetics. It also offers employer and managed care wellness services, digital pathology tools, provider and payer platforms, a patient app for scheduling and test results, and a generative AI test selection tool.
- Headquarters
- Burlington, United States
- Employees
- 71,000
- Founded
- 1971
- Chief executive
- Adam Schechter
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Labcorp HoldingsLH | $29.81B | 11.2% | 30.1 | +42.62% |
| IlluminaILMN | $29.15B | 19.1% | 33.2 | +35.87% |
| Quest DiagnosticsDGX | $28.42B | 14.9% | 25.7 | +33.31% |
| Mettler-Toledo InternationalMTD | $33.15B | 27.8% | 36.2 | +53.96% |
| NateraNTRA | $39.64B | -8.5% | — | +33.42% |
| IQVIA HoldingsIQV | $40.51B | 13.9% | 29.9 | +43.34% |
Same industry or related industries, similar size. Compare Labcorp Holdings with its competitors · Full profile
